CVI
Home Help [Feedback] [For Subscribers] [Archive] [Search] --
CVI Accepts, published online ahead of print on 12 December 2007
This Article
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
CVI.00437-06v1
15/2/382    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ngo, T. D.
Right arrow Articles by Quinn, T. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ngo, T. D.
Right arrow Articles by Quinn, T. C.
Clin. Vaccine Immunol. doi:10.1128/CVI.00437-06
Copyright (c) 2007, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

Use of Commercial Enzyme Immunoassays to Detect Antibodies to the Herpes Simplex Virus Type 2 Glycoprotein G in a Low-risk Population in Hanoi, Vietnam

Thoai D. Ngo, Oliver Laeyendecker, Hanh La, Wayne Hogrefe, Rhoda Ashley Morrow, and Thomas C. Quinn*

National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Epidemiology, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, Maryland; Focus Technologies, Cypress, California; Department of Laboratory of Medicine, University of Washington, Seattle, Washington

* To whom correspondence should be addressed. Email: tquinn{at}jhmi.edu.


  Abstract

Sera from 1,238 Vietnamese women in Hanoi were tested for herpes simplex virus type-2 (HSV-2). HSV-2 prevalence was 2.0%. Kalon and Biokit showed significantly higher concordance to Western blot compared to Focus (p<0.01). Screening by Focus then re-testing with Kalon/Biokit of positive samples can reduce falsely positive results significantly (p<0.01).




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
Antimicrob. Agents Chemother. Clin. Microbiol. Rev. Infect. Immun.
J. Clin. Microbiol. J. Virol. ALL ASM JOURNALS

Copyright © 2007 by the American Society for Microbiology. All rights reserved.